We see around corners on BioTech and life sciences investment in Australia.
The ASX-listed pharmaceutical, biotechnology and life sciences sector has a market value of over AU$150 billion and comprises just under 100 companies. Research and Development tax incentives entice global technologies to Australia.
A decade of development often sits behind successful biotech — and buying and developing an asset can be a financial rollercoaster. Surviving the ups and downs of clinical trials is vital before share prices can accelerate and acquisition becomes likely.
How Acclime can help.
Navigating regulatory landscape
Acclime guides life science businesses in Australia through complex regulations, ensuring compliance for successful trials and commercialisation.
Optimising financial processes
Our financial expertise helps life science companies navigate uncertainties, optimise financial processes, and manage costs effectively.
Intellectual property management
We secure and manage your intellectual property, which is crucial for maximising the value of innovations, especially as acquisitions become likely.
